Company Profile

Industry Sector: Biotech/pharma

Company Overview: Synedgen develops a platform of proprietary polysaccharide derivatives to control microbial populations in biofilms and at tissue interfaces to prevent infection, reduce inflammation and stimulate healing.

Target Market(s): Dermal, ophthalmic, mucosal anti-inflammatory and antibiofilm with wound regenerative capabilities. Primary markets: Oral mucositis treatment, sinusitis treatment, burn and wound infection prophylactic/regenerative therapeutic, ophthalmic drop for enhanced healing and reduced scar formation.

Key Value Drivers

Technology: Topical Treatment for Radiation Induced Oral Mucositis

Competitive Advantages:
- no currently approved treatments
- both regenerative and anti-infective
- out-patient therapeutic
- excellent price point

Plan & Strategy: Take 1-3 products through Phase 2 clinical trials; partner or sell. Support efforts with veterinary products and international cosmetic oral care products.

Management

Board of Directors: William Wiesmann, MD; Larry Shapiro, MD; Gregory Kenton, MD; Diane Olmstead; Clarke Atwell

Leadership & Advisors: William Wiesmann, CEO; Shenda Baker, President; Dr. Steve Sonis, Brigham Women's Hosp.; Dr. Ed Truelove, U. Wash; Dr. Joel Epstein, Cedar Sinai/City of Hope; Dr. Greg Davis, U. Wash.; Dr. John Sheppard, VA Vision Center; Dr. Brian Gilger, NCSU

5 keywords
Biofilm, anti-inflammatory, anti-infective, tissue regeneration, reduced scar formation

Product Pipeline

<table>
<thead>
<tr>
<th>Target</th>
<th>In Vitro Efficacy</th>
<th>In Vivo (status)</th>
<th>Done</th>
<th>Anticipated Human Trial</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sinusitis (CF Patients)</td>
<td>Complete</td>
<td>Ex vivo sputum/mucus</td>
<td>Q03 12</td>
<td></td>
</tr>
<tr>
<td>Oral Mucositis</td>
<td>Complete</td>
<td>Hamsters (ongoing)</td>
<td>Q01 13</td>
<td></td>
</tr>
<tr>
<td>Surgical Site Infection</td>
<td>Complete</td>
<td>Porcine (ongoing)</td>
<td>Q01 13</td>
<td></td>
</tr>
<tr>
<td>Wound Healing</td>
<td>Complete</td>
<td>Porcine (ongoing)</td>
<td>TBD</td>
<td></td>
</tr>
<tr>
<td>Ophthalmic</td>
<td>Complete</td>
<td>Rabbit (ongoing)</td>
<td>TBD</td>
<td></td>
</tr>
</tbody>
</table>